Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Study findings on angiogenesis are outlined in reports from Seoul National University
August 26th, 2008
According to recent research from Seoul, South Korea, "Inhibition of tumor angiogenesis through modulation of vascular endothelial growth factor ( VEGF) and its signaling pathway has been clinically validated as a viable therapeutic modality in the treatment of cancer. The use of artificial transcription factors based on Cys2-His2 zinc-finger proteins ( ZFPs) targeting the VEGF promoter offers a novel strategy for modulating VEGF levels in tumors." "In order to demonstrate the utility of VEGF-targeted ZFPs as therapeutic agents, we generated adenoviruses ( Ads) expressing VEGF promoter-targeted transcriptional repressor ZFP, F435-KOX. A replication-incompetent Ad...
Source: Cancer Weekly (2008-08-26)
|
